Chimeric antigen receptor T cell treatment in hematologic malignancies


GÖKER H. , Malkan U. Y. , DEMİROĞLU H. , BÜYÜKAŞIK Y.

TRANSFUSION AND APHERESIS SCIENCE, vol.54, no.1, pp.35-40, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 54 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1016/j.transci.2016.01.011
  • Title of Journal : TRANSFUSION AND APHERESIS SCIENCE
  • Page Numbers: pp.35-40

Abstract

Adoptive transfer of T cells that have genetically engineered chimeric antigen receptors (CARs) is an encouraging treatment modality in the hematological malignancies. These T cells are capable of selectively recognizing tumor -associated antigens. There are a variety of reported, as well as ongoing studies on the utilization of CART cells in the treatment of leukemia, myeloma, as well as B and T cell lymphomas. In this review, we aimed to highlight current understanding of this promising treatment modality, including its efficacy and adverse effects. (c) 2016 Elsevier Ltd. All rights reserved.